

November 21, 2022

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith a disclosure of Related Party Transactions in the specified format for the half year ended September 30, 2022.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Bliss GVS Pharma Limited**

ADITI
HIMANSHU
U BHATT

Digitally signed by
ADITI HIMANSHU
BHATT
Date: 2022.11.21
20:54:21 +05'30'

Aditi Bhatt
Company Secretary

Encl: as above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Loan and Advances	15000	121.48	8070.93	8804.92	-	-	-	Loan	4.5 %	Repayable on Demand	Unsecured	Loan utilised for business
	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Sale of Goods	500	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Bliss GVS International Pte Ltd	Wholly Owned Subsidiary	Purchase of Goods	20	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Labour Charges and purchases of goods	100	7.45	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Dividend Received	13	12.60	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Investment in Share Capital	2500	-	1,803.00	1,803.00	-	-	-	Investment in equity	NA	NA	Unsecured	Investment made for business purpose
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Interest Income/ Receivable	1	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Sale of Goods	250	0.63	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Kremoint Pharma Pvt Ltd	Subsidiary	Loans and Advances	100	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences Limited (UK)	Wholly Owned Subsidiary	Investment In Share Capital	-	-	0.10	0.10	-	-	-	Investment in equity	NA	NA	Unsecured	Investment made for business purpose

	Bliss GVS Pharma Limited	Asterisk Lifesciences Limited (UK)	Wholly Owned Subsidiary	Loans and Advances	1000	-	19.80	18.05	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences Limited (UK)	Wholly Owned Subsidiary	Interest Income /Receivable	1	0.41	2.50	2.68	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Investment in Share Capital	10	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Reimbursement of Expenses received	50	0.82	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Sale of Goods	15000	2932.94	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences GH Limited	Step-down Subsidiary	Loans and Advances	1000	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Greenlife Bliss Healthcare	Step-down Subsidiary	Loans and Advances	100	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Greenlife Bliss Healthcare	Step-down Subsidiary	Sale of Goods	100	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Greenlife Bliss Healthcare	Step-down Subsidiary	Purchase of Goods	10	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	EIPIL Exports Pvt Ltd.	Step-down Subsidiary	Sale of Goods	500	52.32	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma	Lozen Pharma Pvt Ltd.	Directors are Members/Share holders	Purchase of Goods	750	195.49	-	-							

	Limited															
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Sale of goods	15000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Loans and Advances	1000	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Reimbursement of Expenses	50	2.13	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Asterisk Lifesciences DRC	Step-down Subsidiary	Investment In Share Capital	10	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuities (I) Pvt Ltd	Directors are Members/Share holders	Purchase of Goods	25	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuities (I) Pvt Ltd	Directors are Members/Share holders	Reimbursement of Expenses	3	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Plastic Ingenuities (I) Pvt Ltd	Directors are Members/Share holders	Sales of Goods	5	-	-	-	-	-	-	-	-	-	-	-
	Bliss GVS Pharma Limited	Bliss GVS Charitable Trust	Enterprise over which KMP exercises significant influence	Donation	50	25.00	-	-	-	-	-	-	-	-	-	-
Total (of Note 6b)																

Note: Foreign balances are reinstated wherever applicable

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
 - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 - b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. "Cost" refers to the cost of borrowed funds for the listed entity.
8. PAN will not be displayed on the website of the Stock Exchange(s).
9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.